Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,770
  • Shares Outstanding, K 144,955
  • Annual Sales, $ 148,760 K
  • Annual Income, $ -264,520 K
  • 60-Month Beta 0.24
  • Price/Sales 0.08
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.75
  • Most Recent Earnings $-0.39 on 11/09/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0760 +6.84%
on 12/16/22
0.3772 -78.47%
on 12/01/22
-0.2679 (-76.74%)
since 11/18/22
3-Month
0.0760 +6.84%
on 12/16/22
1.3100 -93.80%
on 10/04/22
-1.0388 (-92.75%)
since 09/20/22
52-Week
0.0760 +6.84%
on 12/16/22
3.3200 -97.55%
on 12/21/21
-3.1288 (-97.47%)
since 12/20/21

Most Recent Stories

More News
Analysts Holding As Pfizer Waits On Two Phase 3 Studies

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

PFE : 27.98 (+0.65%)
MDVN : 81.48 (+0.05%)
AZN : 77.99 (-0.24%)
CLVS : 0.0812 (-5.58%)
TSRO : 74.96 (+0.03%)
BHVN : 34.71 (-1.08%)
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe,...

CLVS : 0.0812 (-5.58%)
Pre-Market Brief: Stocks Mixed As Labor Market Strength Weigh On Sentiment

December S&P 500 futures (ESZ22) are trending down -0.30% this morning after three major US benchmark indices closed mixed on Friday as the November payrolls report fueled expectations the Federal Reserve...

ESZ22 : 3,871.47s (-0.66%)
TXMD : 1.6100 (-7.47%)
IOVA : 8.02 (+0.12%)
IMPP : 3.88 (+1.57%)
CLVS : 0.0812 (-5.58%)
UTHR : 318.55 (+0.51%)
SBUX : 77.85 (-1.75%)
Clovis: Q3 Earnings Snapshot

Clovis: Q3 Earnings Snapshot

CLVS : 0.0812 (-5.58%)
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound,...

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.35 (-2.17%)
CLVS : 0.0812 (-5.58%)
OPK : 1.2500 (-0.79%)
CRDF : 2.22 (-4.72%)
MRK : 123.80 (-4.64%)
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The...

CLVS : 0.0812 (-5.58%)
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35 th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored...

CLVS : 0.0812 (-5.58%)
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved...

CLVS : 0.0812 (-5.58%)
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 ( 177 Lu)...

CLVS : 0.0812 (-5.58%)
Why Clovis Oncology Zoomed 30% Higher Today

The biotech delivers some highly encouraging news on the clinical front.

CLVS : 0.0812 (-5.58%)
BMY : 41.53 (+0.05%)

Business Summary

Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with...

See More

Key Turning Points

3rd Resistance Point 0.1148
2nd Resistance Point 0.1063
1st Resistance Point 0.0937
Last Price 0.0812
1st Support Level 0.0726
2nd Support Level 0.0641
3rd Support Level 0.0515

See More

52-Week High 3.3200
Fibonacci 61.8% 2.0808
Fibonacci 50% 1.6980
Fibonacci 38.2% 1.3152
Last Price 0.0812
52-Week Low 0.0760

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar